All studies
RecruitingTherapeutic confirmatory (Phase III)Interventional

An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis

Multiple sclerosis (MS) affects the brain and spinal cord, and progressive MS causes symptoms to slowly worsen over time. This four-year study is testing how well a medicine named ocrelizumab (Ocrevus) works for people with progressive MS. All participants will receive the treatment as a regular drip into a vein. Before each drip, they will also receive common medicines like paracetamol, an antihistamine, and a steroid to prevent mild infusion reactions. Researchers want to see if the medicine can stop physical and memory problems from getting worse. During the trial, doctors will carry out regular health checks, MRI scans of the brain, simple walking tests, and thinking exercises. Taking part helps doctors learn if ocrelizumab provides long-lasting protection against disease progression.

At a glance

Status
Recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
F. Hoffmann-La Roche AG
Enrolment target
520
Start
18 Mar 2024

What is this study about?

Multiple sclerosis happens when the body's immune system mistakenly attacks the protective layer around nerves in the brain and spinal cord. In progressive forms of MS, people experience a gradual buildup of physical symptoms and memory challenges without distinct periods of full recovery. Finding treatments that can slow down or stop this gradual decline is one of the biggest priorities in MS research today.

This clinical trial is testing a medicine called ocrelizumab, also known by its brand name Ocrevus. Ocrelizumab works by targeting specific immune cells that are thought to play a role in nerve damage. This is an 'open-label' study, which means there is no dummy drug (placebo). Everyone who joins the study will receive the active treatment over a period of four years.

Researchers will closely track whether the drug helps people remain stable. They will test walking speed, hand coordination, memory, tiredness, and pain levels. Patients will also have brain scans (MRIs) to see if the treatment reduces nerve inflammation and protects healthy brain tissue over time.

By gathering detailed information over four full years, this study hopes to give people living with progressive MS, and their doctors, clearer answers on how well ocrelizumab preserves independence and whether it remains safe to use over the long term.

Key takeaways

  • Tests whether ocrelizumab can slow down physical and memory decline in progressive MS.
  • Every participant receives the real medicine; there is no placebo.
  • The treatment is given as a hospital drip roughly every six months over four years.
  • Researchers track progress through walking tests, memory tasks, surveys, and MRI scans.
  • Taking part is voluntary, and you can leave at any time without losing NHS care.

Who may be eligible?

This study is open to adults aged 18 and older who have been diagnosed with progressive multiple sclerosis. Both men and women can join.

To take part, you need to be able to visit a hospital clinic regularly for health checks, tests, and treatment drips. You will also need to be able to complete simple walking tests, memory exercises, and questionnaires about your daily life, as well as lie still for MRI scans.

Certain people may not be able to take part. For instance, having an active, serious infection or other major medical conditions might make the treatment unsafe. Your neurologist or the study team will review your full medical history to confirm whether this trial is safe and suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with progressive multiple sclerosis.
  3. I am able and willing to attend hospital appointments over a four-year period.
  4. I can safely undergo MRI brain scans.
  5. I am happy to receive treatment via a hospital drip into a vein.
Answer every question to see your result.

What does participation involve?

Taking part in this study lasts for four years. You will receive ocrelizumab as a slow drip into a vein at a specialised hospital clinic, usually given every six months. Before each treatment, you will be given standard medicines—such as paracetamol, an antihistamine, and a small dose of steroid—to help prevent allergic reactions or fever during the drip.

Between treatment visits, you will have regular check-ups with the study team. These visits will include blood tests, physical examinations, and detailed tests to check your walking speed and hand movement. You will also do brief memory tests and fill out surveys about fatigue, pain, and how MS affects your day-to-day life. You will also have periodic MRI brain scans to see how your brain is responding to the treatment.

Potential risks and benefits

The main potential benefit is that ocrelizumab may help slow down your MS symptoms and protect your mobility and memory, although this cannot be guaranteed. You will also receive very close, regular health monitoring from MS specialists throughout the four years. However, all medicines carry risks. Common side effects include reactions during the drip (such as itching, rash, or a tickly throat) and a slightly higher risk of minor infections like colds, because the medicine lowers part of your immune system. Taking part is completely voluntary, and you can change your mind and leave the study at any time without it affecting your standard NHS care.

Locations (7)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Netherlands
  • —
    Unverified
    Germany
  • —
    Unverified
    Denmark
  • —
    Unverified
    Poland
  • —
    Unverified
    Czechia
  • —
    Unverified
    France
  • —
    Unverified
    Italy

Common questions

Will I receive a placebo (dummy drug)?

No. This is an open-label study, meaning every person who takes part receives the real medicine (ocrelizumab).

How is the medicine given?

It is given as a liquid drip into a vein at the clinic, usually once every six months, which takes a few hours.

How long will I be in the study?

The study runs for four years, with regular clinic appointments and health assessments throughout that time.

What happens if I experience side effects?

Before each drip, you receive medicines like paracetamol to help prevent reactions. If you feel unwell at any point, the study doctors are available to help manage symptoms and adjust your care.

Can I leave the study early?

Yes. You have the right to withdraw from the trial at any point, for any reason, without giving up your normal medical care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "An Open-Label, Single-Arm 4-Year Study to Evaluate Effective…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.